Boeing and Centene Face Major Financial Setbacks in Q3 2025
Chicago, Wednesday, 29 October 2025.
Boeing and Centene reported significant Q3 2025 losses. Boeing’s losses were due to a $4.9 billion charge on 777X delays, while Centene faced a $6.7 billion goodwill impairment.
Boeing’s Ongoing Challenges
Boeing Company (NYSE: BA) reported a significant GAAP loss of $7.14 per share for the third quarter of 2025. This loss was largely attributed to a substantial $4.9 billion charge related to delays in its 777X program, which has seen its first delivery pushed to 2027 [1][2]. Despite these setbacks, Boeing’s revenue rose by 30% year-over-year to $23.3 billion, driven by increased production and deliveries [2]. The company also achieved positive free cash flow for the first time since late 2023, marking a critical milestone in its recovery efforts [1].
Strategic Adjustments by Boeing
In response to these financial challenges, Boeing has committed to increasing its production of the 737 Max jets from 38 to 42 per month starting October 2025, following an agreement with the Federal Aviation Administration (FAA) [1]. This move is part of a broader strategy to stabilize its operations and improve long-term productivity [1][3]. Additionally, Boeing has been navigating labor unrest, with over 3,200 workers on strike since summer 2025 due to ongoing contract disputes [3].
Centene’s Financial Impairments
Centene Corporation (NYSE: CNC) reported a GAAP diluted loss per share of $13.50 for the third quarter of 2025, primarily due to a $6.7 billion non-cash goodwill impairment [4]. This impairment reflects the company’s adjustments to market conditions, including the impact of the One Big Beautiful Bill Act and a decline in stock price [4]. Despite these losses, Centene reported an adjusted diluted EPS of $0.50, showcasing some underlying strength in its operations [4].
Centene’s Forward-Looking Plans
Looking ahead, Centene has raised its full-year adjusted diluted EPS forecast to at least $2.00, an increase of $0.25 from previous estimates [4]. This optimistic outlook is driven by growth in its Marketplace and Medicare Prescription Drug Plan memberships, which have seen an increase from 25.9 million to 27.9 million in 2025 [4]. The company is also focusing on operational efficiencies, as demonstrated by its cash flow of $1.4 billion provided by operations in Q3 2025 [4].